GSK and Vir are compiling a data package that could back the usage of a higher dose of sotrovimab against BA.2 Omicron sub-variant. Credit: Montgomery County Planning Commission / Flickr .

The US Food and Drug Administration (FDA) has the Emergency Use Authorization (EUA) Fact Sheet, limiting the usage of GlaxoSmithKline (GSK) and 鈥檚 sotrovimab for Covid-19, due to the BA.2 Omicron sub-variant. 

As an investigational monoclonal antibody, sotrovimab attaches to the SARS-CoV-2 virus epitope to neutralise it.

Go deeper with GlobalData

  • ReportsLogo

  • ReportsLogo

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Based on the totality of data available, including Vir鈥檚 new live virus findings, the currently authorised 500mg dose of the antibody is unlikely to be effective against the viral sub-variant, the FDA noted.

According to the latest FDA update, sotrovimab is not intended for usage in Maine, Massachusetts, Connecticut, Rhode Island, Vermont, New Jersey, New Hampshire, New York, Puerto Rico, and the Virgin Islands, US.

Sotrovimab is indicated for use in other regions until the regulatory authority issues further notice. 

According to the previously issued FDA EUA, sotrovimab is intended to treat mild-to-moderate Covid-19 in adults and paediatric patients age 12 years and above, who are at increased risk of disease progression, including hospital admission or death.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The companies are currently compiling a data package that could back the usage of a higher dose of the antibody against the subvariant. 

This package will be submitted to various regulatory and health agencies globally.

Sotrovimab has also obtained marketing authorisation from the European Commission, and conditional marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency, among others.

In a press statement, the FDA said: 鈥淲e will continue to monitor BA.2 in all US regions and may revise the authorisation further, to ensure that patients with Covid-19 have effective treatments available.鈥�